转移性肾细胞癌患者接受抗PD-1免疫检查点抑制剂治疗的粪便微生物组分析
该研究对31例接受纳武利尤单抗(77%)或纳武利尤单抗联合伊匹木单抗(23%)治疗的转移性肾细胞癌患者,在治疗前采集粪便进行微生物组分析,其中58%患者获得临床获益。结果显示,更高的微生物多样性与临床获益相关(p=0.001),且多种菌种与临床获益与否相关。纵向分析表明,获得临床获益的患者中Akkermansia muciniphila的相对丰度增加。
要点
- 治疗前粪便微生物多样性高与CPI临床获益相关(p=0.001)。
- 多种微生物物种与临床获益或缺乏获益相关。
- 临床获益患者中Akkermansia muciniphila相对丰度随时间增加。
核心结论
- 在转移性肾细胞癌患者中,更高的粪便微生物多样性与CPI治疗临床获益相关,且微生物组成随治疗动态变化。
研究设计与样本
- 研究纳入31例接受纳武利尤单抗(77%)或纳武利尤单抗联合伊匹木单抗(23%)治疗的转移性肾细胞癌患者,在治疗前采集粪便,并纵向分析微生物组变化。
主要发现
- 58%的患者获得临床获益;更高的微生物多样性与临床获益相关(p=0.001)。
- 多种微生物物种与临床获益或缺乏获益相关。
- 纵向分析显示,获得临床获益的患者中Akkermansia muciniphila的相对丰度增加。
关键数值与推荐
- 临床获益与更高微生物多样性相关(p=0.001)。
- 临床获益患者中Akkermansia muciniphila相对丰度增加。
临床怎么用
- 粪便微生物组多样性可能作为转移性肾细胞癌患者CPI治疗获益的潜在生物标志物。
- 动态监测微生物组成变化可能为调节微生物组以改善CPI疗效提供机会。
局限性
- 样本量较小(31例),需更大规模研究验证。
- 未报告具体菌种名称及物种与临床获益关联的详细统计数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preclinical models and early clinical data suggest an interplay between the gut microbiome and response to immunotherapy in solid tumors including metastatic renal cell carcinoma (mRCC). We sought to characterize the stool microbiome of mRCC patients receiving a checkpoint inhibitor (CPI) and to assess treatment-related changes in microbiome composition over the course of CPI therapy. Stool was collected from 31 patients before initiation of nivolumab (77%) or nivolumab plus ipilimumab (23%) therapy, of whom 58% experienced clinical benefit. Greater microbial diversity was associated with clinical benefit from CPI therapy (p = 0.001), and multiple species were associated with clinical benefit or lack thereof. Temporal profiling of the microbiome indicated that the relative abundance of Akkermansia muciniphila increased in patients deriving clinical benefit from CPIs. This study substantiates results from previous CPI-related microbiome profiling studies in mRCC. Temporal changes in microbiome composition suggest potential utility in modulating the microbiome for more successful CPI outcomes. PATIENT SUMMARY: We compared the composition and diversity of the gut microbiome in patients receiving immunotherapy for renal cell carcinoma. We found that higher microbial diversity is associated with better treatment outcomes. Treatment response is characterized by changes in microbial species over the course of treatment.
引用
- Salgia NJ, Bergerot PG, Maia MC, et al. Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti-PD-1 Immune Checkpoint Inhibitors. Eur Urol. 2020. PMID: 32828600. doi:10.1016/j.eururo.2020.07.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。